<DOC>
	<DOCNO>NCT00947856</DOCNO>
	<brief_summary>This multicenter , open-label study evaluate safety efficacy treatment brentuximab vedotin ( SGN-35 ) patient previously participate brentuximab vedotin study .</brief_summary>
	<brief_title>A Brentuximab Vedotin Trial Patients Who Have Previously Participated Brentuximab Vedotin Study</brief_title>
	<detailed_description>This multicenter , open-label study evaluate single-agent brentuximab vedotin ( SGN-35 ) treatment patient previously participate brentuximab vedotin study , include Studies SGN35-005 ( NCT01100502 ) , SGN35-007 ( NCT01026233 ) , SGN35-008 ( NCT01026415 ) . Patients treat study ( SGN35-006 ) could re-enroll study eligible . The study consist 2 arm , follow : - Retreatment arm : Patients CD30-positive hematologic malignancy experience complete remission ( CR ) partial remission ( PR ) previous brentuximab vedotin treatment clinical study subsequently experience disease progression relapse . The purpose arm ass safety efficacy retreatment brentuximab vedotin . - Extension treatment arm : Patients either CD30-positive hematologic nonhematologic malignancy complete treatment prior brentuximab vedotin study without unacceptable toxicity experience clinical benefit assess investigator . The purpose arm enable patient participate certain prior brentuximab vedotin trial receive extension treatment assess patient safety survival extension treatment setting .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participated previous brentuximab vedotin study . CD30positive hematologic malignancy . At minimum , experience clinical benefit prior brentuximab vedotin study . For retreatment , patient must previously achieve either complete partial remission brentuximab vedotin experience disease progression discontinue prior brentuximab vedotin study . Withdrew consent participate prior brentuximab vedotin study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Monomethylauristatin E</keyword>
</DOC>